Medical Oncology

, Volume 28, Issue 4, pp 1281–1287 | Cite as

Intima-media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline-based chemotherapy

  • Hana Kalábová
  • Bohuslav Melichar
  • Leoš Ungermann
  • Jiří Doležal
  • Lenka Krčmová
  • Markéta Kašparová
  • Jiří Plíšek
  • Radomír Hyšpler
  • Miroslav Pecka
  • Dagmar Solichová
Original paper


An increased incidence of complications of atherosclerosis has been noted in cancer survivors. The aim of the present study was to evaluate, in patients with breast carcinoma, the effect of antracycline-based chemotherapy on carotid intima-media thickness (IMT), myocardial perfusion, assessed by single-photon emission tomography (SPECT) and laboratory parameters associated with the risk of atherosclerosis. Thirty-six patients with breast cancer were evaluated before and after anthracycline-based chemotherapy. Retinol, alpha-tocopherol, glycosylated hemoglobin and urinary neopterin were measured by high-performance liquid chromatography. Peripheral blood cell count, D-dimers, fibrinogen, antithrombin, glucose, magnesium, creatinine, uric acid, albumin, C-reactive protein, lipoprotein (a), cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, homocysteine, urinary albumin and N-acetyl-beta-d-glucosaminidase (NAG) were determined with routine methods. No significant differences were observed between patients and 16 controls. Compared to the measurement before the start of therapy, peripheral blood leukocyte and platelet count, hemoglobin, creatinine, HDL cholesterol, retinol, albumin, urinary albumin and NAG decreased, and total cholesterol, LDL cholesterol, triglycerides, neopterin and mean IMT increased significantly after the treatment. Of the 36 patients who had SPECT after treatment, perfusion defects were noted only in two cases, including the patient who had perfusion defects at baseline examination and a patient who did not have a baseline SPECT. In conclusion, a significant increase in carotid IMT, total cholesterol, LDL cholesterol, triglycerides and urinary neopterin and a decrease of peripheral blood leukocyte and platelet counts, hemoglobin, creatinine, HDL cholesterol, retinol, albumin and NAG were observed after the treatment.


Atherosclerosis Cancer Intima-media thickness Single-photon emission computed tomography 


  1. 1.
    Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120:104–10.PubMedGoogle Scholar
  2. 2.
    Ogawa A, Kanda T, Sugihara S, Masumo H, Kobayashi I. Risk factors for myocardial infarction in cancer patients. J Med. 1995;26:221–33.PubMedGoogle Scholar
  3. 3.
    Huddart RA, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21:1513–23.PubMedCrossRefGoogle Scholar
  4. 4.
    Meinardi MT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000;18:1725–32.PubMedGoogle Scholar
  5. 5.
    Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality after cure of testicular seminoma. J Clin Oncol. 2004;22:640–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Nuver J, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer. 2004;40:701–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Kopelson G, Herwig KJ. The etiologies of coronary artery disease in cancer patients. Int J Radiat Oncol Biol Phys. 1978;4:895–906.PubMedGoogle Scholar
  8. 8.
    Pehrsson SK, Linnersjo A, Hammar N. Cancer risk of patients with ischaemic syndromes. J Intern Med. 2005;258:124–32.PubMedCrossRefGoogle Scholar
  9. 9.
    Jagsi R, Grifith KA, Koelling T, Roberts R, Pierce LJ. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer. 2007;109:650–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Jagsi R, Grifith KA, Koelling T, Roberts R, Pierce LJ. Stroke rates and risk factors in patients treated with radiation therapy for early-stage breast cancer. J Clin Oncol. 2006;24:2779–85.PubMedCrossRefGoogle Scholar
  11. 11.
    Ridker PM. Novel risk factors and markers for coronary disease. Adv Intern Med. 2000;45:391–419.PubMedGoogle Scholar
  12. 12.
    Grammer TB, Fuchs D, Boehm BO, Winkelmann BR, Maerz W. Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography in the Ludwigshafen Risk and Cardiovascular Health Study. Clin Chem. 2009;55:1135–46.PubMedCrossRefGoogle Scholar
  13. 13.
    Hachamovitch R, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death. Circulation. 1998;97:535–43.PubMedGoogle Scholar
  14. 14.
    De Lorenzo A, Lima RSL, Siqueira-Filho AG, Pantoja MR. Prevalence and prognostic value of perfusion defects detected by stress technetium-99 m sestamibi myocardial perfusion single-photon emission computed tomography in asymptomatic patients with diabetes mellitus and no known coronary artery disease. Am J Cardiol. 2002;90:827–32.PubMedCrossRefGoogle Scholar
  15. 15.
    Nguyen-Thanh H-T, Benzaquen BS. Screening for subclinical coronary artery disease measuring carotid intima media thickness. Am J Cardiol. 2009;104:1383–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Melichar B, et al. Urinary neopterin, hemoglobin and peripheral blood cell counts in breast carcinoma patients treated with dose-dense chemotherapy. Anticancer Res. 2008;28:2389–96.PubMedGoogle Scholar
  17. 17.
    Melichar B, et al. Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma. Anticancer Res. 2009;29:3337–46.PubMedGoogle Scholar
  18. 18.
    Melichar B, et al. Serum homocysteine, cholesterol, retinol, α-tocopherol, glycosylated hemoglobin and inflammatory response during therapy with bevacizumab, oxaliplatin, 5-fluorouracil and leucovorin. Anticancer Res. 2009;29:4813–20.PubMedGoogle Scholar
  19. 19.
    Melichar B, et al. Association between renal tubular cell dysfunction and increased urinary zinc excretion in cancer patients. Scand J Clin Lab Inv. 1995;55:149–52.CrossRefGoogle Scholar
  20. 20.
    Roman MJ, et al. Clinical application of noninvasive vascular ultrasound in cardiovascular risk stratification: a report from the American Society of Echocardiography and the Society for Vasular Medicine and Biology. Vasc Med. 2006;11:201–11.PubMedCrossRefGoogle Scholar
  21. 21.
    Morales M, et al. Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer. Breast Cancer Res Treat. 1996;40:265–70.PubMedCrossRefGoogle Scholar
  22. 22.
    Tivesten A, et al. Circulating estradiol is an independent predictor of progression of carotid artery intima-media thickness in middle-aged men. J Clin Endocrinol. 2006;9:4433–7.CrossRefGoogle Scholar
  23. 23.
    Dorresteijn LDA, et al. Increased carotid wall thickening after radiotherapy in the neck. Eur J Cancer. 2005;41:1026–30.PubMedCrossRefGoogle Scholar
  24. 24.
    Simon T, et al. Influence of tamoxifen on carotid intima-media thickness in postmenopausal women. Circulation. 2002;106:2925–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Stamatelopoulos KS, et al. Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women. Am Heart J. 2004;147:1093–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Nuver J, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol. 2005;23:9130–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Tzonevska A, Tzvetkov K, Parvanova V, Dimitrova M. 99mTc-MIBI myocardial perfusion scitigraphy for assessment of myocardial damage after radiotherapy in patients with breast cancer. J BUON. 2006;11:505–9.PubMedGoogle Scholar
  28. 28.
    Hardenbergh PH, et al. Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. Int J Radiat Oncol Biol Phys. 2001;49:1023–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Correa CR, et al. Association between tangential beam treatment and cardiac abnormalities after definitive radiation treatment for left-sided breast cancer. Int J Radiat Oncol Biol Phys. 2008;72:508–16.PubMedCrossRefGoogle Scholar
  30. 30.
    Chandra S, Lenihan DJ, Wei W, Yusuf SW, Tong AT. Myocardial perfusion imaging and cardiovascular outcomes in a cancer population. Tex Heart Inst J. 2009;36:205–13.PubMedGoogle Scholar
  31. 31.
    Hansson G. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.PubMedCrossRefGoogle Scholar
  32. 32.
    Espinola-Klein C, et al. Impact of intectious burden on progression of carotid atherosclerosis. Stroke. 2002;33:2581–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Debier C, Larondelle Y. Vitamins A and E: metabolism, roles and transfer to offspring. Br J Nutr. 2005;93:153–74.PubMedCrossRefGoogle Scholar
  34. 34.
    Banks RE, et al. The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol. 1995;102:217–23.PubMedCrossRefGoogle Scholar
  35. 35.
    McMillan DC, et al. The relationship between reduced vitamin antioxidant concentrations and the systemic inflammatory response in patients with common solid tumours. Clin Nutr. 2002;21:161–4.PubMedCrossRefGoogle Scholar
  36. 36.
    Mayland C, Allen KR, Degg TJ, Bennet M. Micronutrient concentrations in patients with malignant disease: effect of the inflammatory response. Ann Clin Biochem. 2004;41:138–41.PubMedCrossRefGoogle Scholar
  37. 37.
    Kralickova P, Melichar B, Malir F, Roubal T. Renal tubular dysfunction and urinary zinc excretion in breast cancer patients treated with anthracycline-based combination chemotherapy. J Exp Clin Cancer Res. 2004;23:579–84.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Hana Kalábová
    • 1
  • Bohuslav Melichar
    • 2
    • 8
  • Leoš Ungermann
    • 3
  • Jiří Doležal
    • 4
  • Lenka Krčmová
    • 5
    • 7
  • Markéta Kašparová
    • 5
    • 7
  • Jiří Plíšek
    • 5
    • 7
  • Radomír Hyšpler
    • 5
  • Miroslav Pecka
    • 6
  • Dagmar Solichová
    • 5
  1. 1.Department of Oncology and RadiotherapyCharles University School of MedicineHradec KraloveCzech Republic
  2. 2.Institute of Experimental NeurosurgeryCharles University School of MedicineHradec KraloveCzech Republic
  3. 3.Department of RadiologyCharles University School of MedicineHradec KraloveCzech Republic
  4. 4.Department of Nuclear MedicineCharles University School of MedicineHradec KraloveCzech Republic
  5. 5.Department of Gerontology and Metabolic CareCharles University School of MedicineHradec KraloveCzech Republic
  6. 6.Department of HematologyCharles University School of MedicineHradec KraloveCzech Republic
  7. 7.Department of Analytical ChemistryCharles University School of PharmacyHradec KraloveCzech Republic
  8. 8.Department of OncologyPalacký University Medical School Teaching HospitalOlomoucCzech Republic

Personalised recommendations